References

* 1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 2nd edn. Cephalalgia. 2004; 24: 1-150.

2. Russell M, Rasmussen BK, Brennum J etal. Presentation of a new instrument. The diagnostic headache diary. Cephalalgia. 1992; 12: 369-74.

3. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. Journal of Clinical Epidemiology. 1991; 44: 1147-57.

4. Gobel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the Headache Classification of the International Headache Society. Cephalalgia. 1994; 14: 97-106.

5. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of subtypes of migraine. International Journal of Epidemiology. 1995; 24: 612-18.

6. Rasmussen BK, Stewart WF. Epidemiology of migraine. In Olesen J, Tfelt-Hansen P, Welch KMA (eds). The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000: 227-33.

7. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998; 279: 381-3.

8. Iversen HK, Langemark M, Andersson PG et al. Clinical characteristics of migraine and tension-type headache in relation to new and old diagnostic criteria. Headache. 1990; 30: 514-19.

* 9. Goadsby P, Tfelt-Hansen P. Cluster headache:

introduction and epidemiology. In: Olesen J, Tfelt-Hansen P, Goadsby PJ etal. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 743-5.

10. Rasmussen BK. Migraine and tension-type headache in a general population: Precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 1993; 53: 65-72.

11. Kudrow L. Muscle contraction headaches. In: Clifford Rose F (ed.). Handbook of clinical neurology. Headache. Amsterdam: Elsevier Science, 1986. 4: 343-52.

12. Langemark M, Olesen J, Poulsen DL, Bech P. Clinical characterization of patients with chronic tension headache. Headache. 1988; 28: 590-6.

13. Rasmussen BK. Migraine and TTH in a general population: psychosocial factors. International Journal of Epidemiology. 1992; 21: 1138-43.

14. Olesen J. Clinical characterization of tension headache. In: Olesen J, Edvinsson L (eds). Basic mechanisms of headache. Amsterdam: Elsevier Science, 1988: 9-14.

15. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Prognosis of migraine and tension-type headache: a population-based follow-up study. Neurology. 2005; 65: 580-5.

* 16. Olesen J, Goadsby PJ, Ramadan N et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott, Williams Ö Wilkins, 2006.

17. Ophoff RA, Terwindt GM, Vergouwe MN et al. Familial hemiplegic migraine and epidodic ataxia type-2 are caused by mutations in the Ca21 channel gene CACNL1A4. Cell. 1996; 87: 543-52.

18. Terwindt GM, Ophoff RA, Haan J et al. Migraine, ataxia and epilepsy: a challenging spectrum of genetic determined calcium channelopathies. European Journal of Human Genetics. 1998; 6: 297-307.

19. Ferrari MD, Haan J, Palotie A. Genetic of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams Ö Wilkins, 2006: 251-68.

20. Russell M. Genetic epidemiology of migraine and cluster-headache. Cephalalgia. 1997; 17: 683-701.

21. Ulrich V, Gervil M, Olesen J. The relative influence of environment and genes in episodic tension-type headache. Neurology 2004; 62: 2065-9.

22. Ulrich V, Russell MB, Jensen R, Olesen J. A comparison of tension-type headache in migraineurs and in non-migraineurs: a population-based study. Pain. 1996; 67: 501-06.

23. Aurora SK, Welch KMA. Brain hyperexcitability in migraine: evidence from transcranial magnetic stimulation studies. Current Opinion in Neurology. 1998; 11: 205-09.

24. Fabricius M, Fuhr S, Bhatia R et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain. 2006; 129: 778-90.

25. Hadjikhani N, Sanchez Del Rio M, Wu O et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 4687-92.

26. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Annals of Neurology. 1981; 9: 344-52.

27. Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nature Medicine. 1995; 1: 658-60.

28. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet. 1990; 336: 837-9.

29. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet. 1991; 338: 13-17.

30. Zwetsloot CP, Caekebe JF, Ferrari MD. Lack of asymmetry of middle artery blood flow velocity in unilateral migraine. Stroke. 1993; 24: 1335-8.

31. Iversen HK, Thomsen LL, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996; 16: 412-18.

32. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. European Journal of Neurology. 1994; 1: 73-80.

33. Olesen J, Iversen HK, Thomsen LL. Nitric oxide hypersensitivity. A possible molecular mechanisms of migraine pain. Neuroreport. 1993; 4: 1027-30.

34. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43: 242-6.

35. Buzzi MG, Carter WB, Shimizu T et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology. 1991; 30: 1193-200.

36. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes in human and cats. Annals of Neurology 1993; 33: 48-56.

37. Tvedskov JF, Lipka K, Ashina M et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Annals of Neurology. 2005; 58: 561-8.

38. Lassen LH, Haderslev PA, Jacobsen VB et al. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61.

39. Olesen J, Diener HC, Hustedt IW et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine. 2005; 350: 1104-10.

40. Mitsikostas DD, Thomas AM. Comorbidity of headache and depressive disorders. Cephalagia. 1999; 19: 211-17.

41. Holroyd KA, France JL, Nash JM, Hursey KG. Pain state as artefact in the psychological assessment of recurrent headache sufferers. Pain. 1993; 53: 229-35.

42. Janke EA, Holroyd KA, Romanek K. Depression increases onset of tension-type headache following laboratory stress. Pain. 2004; 111: 230-8.

43. Bendtsen L, Treede RD. Sensitization of myofascial pain pathways in tension-type headaches. In: Olesen J, Goadsby PJ, Ramadan N (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 635-9.

44. Ashina S, Babenko L, Jensen R et al. Increased muscular and cutaneous pain sensitivity in cephalic region in patients with chronic tension-type headache. European Journal of Neurology. 2005; 12: 543-9.

45. Christensen M, Bendtsen L, Ashina M, Jensen R. Experimental induction of muscle tenderness and headache in tension-type headache patients. Cephalalgia. 2005; 25: 1061-7.

46. Ashina M, Stallknecht B, Bendtsen L et al. Tender points are not sites of ongoing inflammation - in vivo evidence in patients with chronic tension-type headache. Cephalalgia. 2003; 23: 109-16.

47. Ashina S, Bendtsen L, Ashina M. Pathophysiology of tension-type headache. Current Pain and Headache Reports. 2005; 9: 415-22.

48. Ashina S, Bendtsen L, Ashina M et al. Evidence for generalized muscular and cutaneous hyperalgesia in patients with chronic tension-type headache. Cephalalgia. 2006; 26: 940-8.

49. Schmidt-Wilcke T, Leinisch E, Straube A et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005; 65: 1483-6.

50. Bendtsen L. Central sensitization in tension-type headache-possible pathophysiological mechanisms. Cephalalgia. 2000; 20: 486-508.

51. May A, Bahra A, Buchel C et al. Hypothalamic activation in cluster headache attacks. Lancet. 1998; 352: 275-8.

52. Wober-Bingol C, Wober C, Zeiler K et al. Tension headache and the cervical spine - plain X-ray findings. Cephalalgia. 1992; 12: 152-4.

53. Zwart JA. Neck mobility in different headache disorders. Headache. 1997; 37: 6-11.

54. Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. Headache. 1998; 38: 10-17.

55. Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache centre. Neurology. 1998; 51: 245-9.

56. Skau M, Brennum J, Gjerris F, Jensen R. What is new about idiopatic intracranial hypertension? An updated review of mechanism and treatment. Cephalalgia. 2006; 26: 384-99.

57. Rapoport A, Stann P, Gutterman DL et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache. 1996; 36: 14-19.

58. Schnieder P, Aull S, Baumgartner C et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia. 1996; 16: 481-5.

59. Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia. 2005; 25: 1159-67.

60. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: effect of a 2-month drug-free period. Neurology. 2006; 66: 1894-8.

61. Tfelt-Hansen P, Rolan P. Nonsteroidal antiinflammatory drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 449-57.

62. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 469-503.

63. Mathew N, Tfelt-Hansen P. General and pharmacological approach to management of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 433-40.

64. Tfelt-Hansen P, Young WB, Silberstein SD. Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 505-13.

65. Tfelt-Hansen P, DeVries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-87.

66. Tfelt-Hansen P. A review of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia. 2006; 26: 1265-74.

67. Lainez MJ, Galvan J, Heras J, Vila C. Crossover, doubleblind clinical trial comparing almotriptan an ergotamine plus caffeine for acute migraine therapy. European Journal of Neurology. 2007; 14: 269-75.

68. Diener HC, Bussone G, de Liang H et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947-54.

69. Tfelt-Hansen P. Triptans vs. other classes of migraine medication. Cephalalgia. 2006; 26: 628.

70. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 459-67.

71. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine patients. British Journal of Clinical Pharmacology. 1983; 16: 695-9.

72. Tfelt-Hansen P, Saxena PR, Dahlof C et al. Ergotamine in the acute treatment of migraine - European Consensus. Brain. 2000; 123: 9-18.

73. Humphrey PP, Feniuk W, Perren MJ et al. The pharmacology of the novel 5-HT1-like agonist GR43175. Cephalalgia. 1989; 9: 23-33.

74. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994; 47: 622-51.

75. Ferrari MD, Saxena PR. Clinical and experimental effect of sumatriptan in humans. Trends in Pharmacological Sciences. 1993; 14: 129-33.

76. Ahn AH, Goadsby PJ. Animal models of headache. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams Ö Wilkins, 2006: 213-19.

77. Gomez-Mancilla B, Cutler NR, Leibowitz MT et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in migraine. Cephalalgia. 2001; 21: 727-32.

78. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine: a meta-analysis of 53 trials. Lancet. 2001; 358: 1668-75.

79. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-58.

80. Diener HC, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. European Journal of Neurology. 2004; 11: 125-34.

81. Tfelt-Hansen P, Henry P, Mulder K et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995; 346: 923-6.

82. Diener HC, Bussone G, de Liano H et al. EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947-54.

83. Diener HC, Eikerman A, Gessner U et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. European Neurology. 2004; 52: 50-6.

84. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache. 2004; 44: 669-73.

85. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tables 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clinical Therapeutics. 2005; 27: 1785-94.

86. Carpay J, Schoenen J, Ahmad F et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clinical Therapeutics. 2004; 26: 214-23.

87. Gaist D, Andersen M, Aarup AL et al. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. British Journal of Clinical Pharmacology. 1997; 43: 429-33.

88. Gaist D, Tsiropoulos, Sindrup SH et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ. 1998; 316: 1352-3.

89. Diener HC, Silberstein SD. Medication overuse headaches. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams Ö Wilkins, 2006: 971-80.

90. Farkilä M, Olesen J, Dahlof C et al. Eletriptan for the treatment of migraine in patients with a previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003; 23: 463-71.

91. Mathew N, Schoenen J. Acute pharmacotherapy of tension-type headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). The headaches, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000: 661-6.

92. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tensiontype headache: a placebo-controlled dose-ranging comparison with paracetamol. Cephalagia. 2003; 23: 59-66.

93. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of TTH. A double blind, placebo controlled study. Headache. 1987; 27: 90-5.

94. Dahlhöf CGH, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia. 1998; 16: 117-23.

95. Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia. 1998; 18: 38-43.

96. Van Gerven JMA, Schoemaker RC, Jacobs LD et al. Self-medication of a single episode of tension-type headache with ketoprofen, ibuprofen and placebo, home-monitored with an electronic patient diary. British Journal of Clinical Pharmacology. 1996; 42: 475-81.

97. Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension-type headache. Neurology. 1998; 50: 507-09.

98. Bove G, Nielsson N. Spinal manipulation in the treatment of episodic tension-type headache. A randomized controlled trial. JAMA. 1998; 280: 1576-9.

99. Evers S, Afra J, Frese A et al. (Members of the task force). EFNS guidelines on the drug treatment of migraine -report of an EFNS task force. European Journal of Neurology. 2006; 13: 560-72.

100. Silberstein SD, Tfelt-Hansen P. Antiepileptic drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Goadsby PJ et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 545-51.

101. Toda N, Tfelt-Hansen P. Calcium antagonists in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 539-44.

102. Tfelt-Hansen P, Rolan P. ß-Adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 519-28.

103. Tfelt-Hansen P, Saxena PR. Antiserotonin drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Goadsby PJ et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 529-37.

104. Tfelt-Hansen P. Prioritizing prophylactic treatment of migraines. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 567-8.

105. Tronvik E, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289: 65-9.

106. Mylecharane EJ, Tfelt-Hansen P. Nonsteroidal antiinflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000: 489-98.

107. Bendtsen L, Mathew N. Prophylactic pharmacotherapy of tension-type headache. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 735-42.

108. Bendtsen L, Jensen R, Olesen J. A nonselective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. Journal of Neurology, Neurosurgery, and Psychiatry. 1996; 61: 285-90.

109. Bendtsen L. Efficacy of antidepressants in headache prophylaxis. In: Olesen J, Silberstein P (eds). Preventive pharmacotherapy of headache disorders, 12th edn. New York: Oxford University Press, 2004: 103-11.

110. Cerbo R, Barbananti P, Fabbrini G et al. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenic implications. Headache. 1998; 38: 453-7.

111. Oguzhanoglu A, Sahiner T, Kurt T, Akalin O. Use of amitriptyline and fluoxetine in the prophylaxis of migraine and tension-type headaches. Cephalalgia. 1999; 19: 531-2.

112. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment treatment of chronic tension-type headache. Neurology. 2004; 62: 1706-11.

113. Bendtsen L, Buchgreitz L Ashina S, Jensen R. Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache. European Journal of Neurology. 2007; 14: 187-93.

114. Hammill JM, Cook TM, Rosecrane JC. Effectiveness of a physical therapy regimen in the treatment of tension-type headache. Headache. 1996; 36: 149-53.

115. Jensen R, Olesen J. Is there an effect of physiotherapy in tension-type headache? Cephalalgia. 1995; 15: 152.

116. Torelli P, Jensen R, Olesen J. Physiotherapy for tensiontype headache: a controlled study. Cephalalgia. 2004; 24: 29-36.

117. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? Cephalalgia. 2006; 26: 769-71.

118. Silberstein SD, Gobel H, Jensen R et al. Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006; 26: 790-800.

119. Sandrini G, Ward TN. Acute treatment of cluster headaches. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 803-07.

120. van Vielt JA, Bahra A, Martin V et al. Intranasal sumatriptan in cluster headache: randomized, doubleblind placebo-controlled study. Neurology. 2003; 60: 630-3.

121. Cittadini E, May A, Straube A et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Archives of Neurology. 2006; 63: 1537-42.

122. Leone M, Rapoport A. Preventive and surgical management of cluster headache. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 809-14.

123. Ambrosini A, Vandenheede M, Rossi P et al. Suboccipital injection with a mixture of rapid-and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain. 2005; 118: 92-6.

How to Stop Your Depression Now

How to Stop Your Depression Now

Finally, Retired Clinical Counsellor Reveals the Secrets Successful Psychiatrists and Psychologists Don't Want You to Know. How to Stop Your Depression Now Reclaim Yourself and Live Again Get the Depression Busting Tools You Need To Win the War Against Depression. Depression is an illness that many people often sweep under a rug. However if depression is left untreated... Your life can become a living nightmare. Depression is a growing epidemic in the US, but it never gets the urgent attention it deserves. You need help and you need it now.

Get My Free Ebook


Post a comment